Business

Ubigene Showcases CRISPR-iScreen™ Platform for Precision CRISPR Screening

Busines Newswire

NEW YORK, January 2026 – Ubigene, a global biotechnology innovator specializing in precision gene editing solutions, today highlights its proprietary CRISPR-iScreen platform, a high-efficiency CRISPR screening technology designed to support both in vivo and in vitro functional genomics research. The platform addresses growing industry demand for more reliable, scalable, and biologically relevant screening strategies in translational research and drug target discovery.

As CRISPR gene editing continues to transform early-stage research, scientists increasingly rely on large-scale functional screens to uncover gene function and therapeutic vulnerabilities. While in vitro screening remains a critical discovery tool, the complexity of biological systems has driven greater adoption of in vivo CRISPR screening to validate targets under physiologically relevant conditions. Ubigene’s CRISPR-iScreen platform was developed to support this multi-layered approach, combining experimental robustness with analytical accessibility.

Proprietary CRISPR-iScreen Technology Enables High-Quality Screening Data

CRISPR-iScreen is independently developed by Ubigene to deliver high-efficiency, high-precision CRISPR screening for gene function characterization and mechanistic studies. Central to the platform is Ubigene’s library-specific competent cell technology, which achieves exceptional DNA uptake efficiency and minimizes background mutations during plasmid amplification. As a result, CRISPR libraries generated through this system demonstrate greater than 99% coverage with less than 10% uniformity variation, supporting reproducible and statistically robust screening outcomes.

In addition, Ubigene employs an exclusive cell pool preparation process optimized for large-scale library production. This standardized workflow minimizes batch-to-batch variability while maintaining up to 99% library coverage, providing a consistent foundation for both exploratory and validation-stage CRISPR screening projects.

Flexible Screening Platforms for Diverse Experimental Designs

Ubigene offers end-to-end CRISPR screening services spanning in vitro and in vivo models, enabling researchers to tailor experimental designs to specific biological questions. The screening platform supports a broad range of experimental conditions, including compound treatment, serial passaging, viral infection models, and flow cytometry–based selection strategies. Multiple enrichment and selection options allow researchers to optimize workflows for oncology, immunology, functional genomics, and other research areas where gene behavior is strongly context-dependent.

This flexibility reflects a broader industry shift toward integrated research strategies that combine computational analysis, in vitro discovery, and in vivo validation to improve confidence in downstream research decisions.

iScreenAnlys Simplifies CRISPR Screening Data Analysis

To further accelerate discovery, Ubigene developed iScreenAnlys, an interactive CRISPR screening data analysis system designed for accessibility and efficiency. The platform requires no coding or bioinformatics expertise, offering an intuitive interface that integrates multiple statistical algorithms and customizable visualization tools. Researchers can rapidly build personalized analysis pipelines and generate publication-ready figures and reports, streamlining interpretation of complex screening datasets.

Extensive CRISPR Library Resources Available

Ubigene maintains one of the industry’s most comprehensive CRISPR library inventories, supporting rapid project initiation and scalability. Available resources include:

These in-stock resources allow researchers to move quickly from experimental design to execution, reducing project timelines without compromising data quality.

By integrating proprietary screening technologies, flexible experimental platforms, and accessible data analysis tools, Ubigene continues to support the scientific community in addressing the practical challenges of modern CRISPR screening. The company remains focused on enabling researchers to evaluate gene function with greater precision and biological relevance across diverse research applications.

About Ubigene

Ubigene is a global biotech innovator dedicated to precision gene editing, cell biology technologies, and antibody validation. Co-founded by leading biological scientists from China, the United States, and France, Ubigene supports researchers in over 40 countries with customized gene-editing solutions designed to advance scientific discovery and translational research.

Media Contact

Organization: Ubigene Biosciences
Contact Person: Shirley Chen
Email: info@ubigene.com
Website: https://www.ubigene.us/